Agilus Diagnostics to withdraw DRHP filed with market regulator Sebi

Diagnostic services provider Agilus Diagnostics announced on Tuesday that it will withdraw its draft red herring prospectus (DRHP) filed with the Securities and Exchange Board of India (Sebi). After the decision was announced late Tuesday night, Fortis Healthcare stock fell 3.23 percent in morning trade around 11 am. The company said in its regulatory filing that the decision to withdraw the DRHP has been taken due to commercial considerations and in consultation and mutual agreement with the private equity investors of Agilus and its board of directors, the company said in a regulatory filing on the Bombay Stock Exchange (BSE).